Psychiatric, behavioral, and cognitive disorders in patients with extracranial cancers

Gabriella Pravettoni,1,2 Bernardo Dell’Osso,3,4,5,9 Tommaso Bocci,6,7 Francesca Cortese,7,8 Roberta Ferrucca,7,9 Valentina Lampis,1 Chiara Rosci,10 and Alberto Priori9,10*

1 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
2 Psycho-Oncology Division, European Institute of Oncology, Milan, Italy
3 Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
4 Department of Mental Health, Fondazione IRCCS Ca’ Granda Policlinico, Milan, Italy
5 Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford University, Stanford, California, USA
6 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
7 Unit of Clinical Neurophysiology, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy
8 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
9 “Aldo Ravelli” Research Center for Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy
10 Neurology Section, ASST Santi Paolo e Carlo, Milan, Italy

Patients with cancer may report neuropsychiatric abnormalities including cognitive impairment, behavioral disturbances, and psychiatric disorders that potentially worsen their quality of life, reduce their treatment response, and aggravate their overall prognosis. Neuropsychiatric disturbances have a different pathophysiology, including immuno-inflammatory and neuroendocrine mechanisms, as a consequence of oncologic treatments (chemo- and radiotherapy). Among clinicians involved in the management of such patients, psychiatrists need to pay particular attention in recognizing behavioral disturbances that arise in oncologic patients, and determining those that may be effectively treated with psychotropic medications, psychotherapeutic interventions, and an integration of them. Through the contribution of different clinicians actively involved in the management of oncological patients, the present review is ultimately aimed at updating psychiatrists in relation to the pathophysiological mechanisms responsible for the onset of cognitive, affective, and behavioral syndromes in these patients, along with epidemiologic and clinical considerations and therapeutic perspectives.

Received 4 September 2017; Accepted 20 November 2017

Key words: Cognitive impairment, extracranial cancer, neuropathology, psychiatric symptoms, treatment.

Introduction

Before their clinical manifestations, tumors (arising outside the brain and without direct diffusion to it) may elicit changes of neuronal function. Additionally, when facing a patient with clinically manifest cancer, the clinician should remember that the disease might induce distant effects due to nervous system involvement even without direct invasion of the nervous tissue. Finally, several drugs and other treatments used by oncologists can impair brain functions.

Tumor-related alterations cause cognitive, affective, and behavioral manifestations that can, in turn, influence the response of the patient to treatments and worsen the disease burden, ultimately increasing its social cost. Thus, the prompt recognition of tumor-related cognitive, affective, and behavioral abnormalities is important for their appropriate management and treatment.

Here, we review the clinical picture, pathophysiology, diagnosis, and management of the main tumor-related and treatment-related cognitive, affective, and behavioral syndromes in patients with cancer.

Search Strategy

References for this review were identified through searches of PubMed, Google Scholar, and MEDLINE.

Pathogenesis

In the absence of any direct brain involvement, cancers may alter its functions through either the induction of a systemic inflammatory response or the action of neural antibodies (see Table 1). A large amount of evidence shows a correlation between cancer and high levels of pro-inflammatory cytokines, suggesting a link between depressive symptoms in cancer patients and their inflammatory status. In animal models, depressive-like symptoms were induced by pro-inflammatory cytokines: the administration of IL-1β or TNF-α to rats and mice induced dose- and time-dependent behavioral disturbances (decreased motor activity, social withdrawal, anorexia, increased slow-wave sleep, cognitive alterations, and increased pain sensitivity). Bouchard et al. examined the relationship between depressive symptoms and inflammation in women with early-stage breast cancer. They found that depression correlated with increased levels of proinflammatory cytokines such as IL-1β and IL-6 and, in particular, with higher levels of TNF-α. In addition, cytokine administration in patients with melanoma frequently induced depressive symptoms, including suicidal ideation.

An interesting finding was that immune system activation resulting from the systemic administration of IL-2 and IFN-α to cancer patients decreased plasma tryptophan levels, and this reduction correlated with the depressive symptoms. Decreased tryptophan could be due to the activation (mediated by pro-inflammatory cytokines, including IFN-γ and TNF-α) of enzymes involved in tryptophan degradation. Since tryptofan is the precursor of the neurotransmitter 5-hydroxytryptamine (serotonin), a decreased tryptophan bioavailability can lead to decreased serotonin synthesis. Increased tryptophan catabolism has been found in several malignancies.

The pathophysiological mechanisms of paraneoplastic syndromes have been also associated with the presence of either intracellular (anti-Hu, anti-Yo, anti-Ma, and C2/CRMP5) or neuronal-surface (NMDAR, AMPAR, and GABAAR) antibodies. In the first case, because the targets are deeply located within cells, is thought that T-cell cytotoxicity is a key mechanism underlying the neuronal deficit. The proposed pathogenetic mechanisms for cognitive and behavioral dysfunction in patients with cancer are summarized in Table 1.

<table>
<thead>
<tr>
<th>Proposed pathogenetic mechanism</th>
<th>References</th>
<th>Primary disease (worldwide incidence as a percentage of all the tumors)</th>
<th>Molecular mechanism</th>
<th>Number of cases (% of cognitive or behavioral impairment)</th>
<th>Symptoms and clinical syndromes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pro-inflammatory cytokines</td>
<td>13</td>
<td>Lung (12.9%)</td>
<td>II-6, TNF-α (sputum)</td>
<td>64 (39%)</td>
<td>Major depression</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Breast (11.9%)</td>
<td>II-1β, II-6, TNF-α (blood)</td>
<td>89 (40%)</td>
<td></td>
</tr>
<tr>
<td>Plasma tryptophan (via kynurenic pathway)</td>
<td>14</td>
<td>Pancreas (2.4%)</td>
<td>kynurenic/tryptophan ratio</td>
<td>17 (100%)</td>
<td>Major depression</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>Breast (11.9%)</td>
<td></td>
<td>80 (36%)</td>
<td></td>
</tr>
<tr>
<td>Paraneoplastic syndromes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracellular antibodies</td>
<td>16-18</td>
<td>SCLC</td>
<td>Anti-Hu</td>
<td>16 (87%)</td>
<td>Dementia, confusion, hallucinations, limbic encephalitis</td>
</tr>
<tr>
<td></td>
<td>19</td>
<td>TGCT (0.4%), Lung cancer* Other*</td>
<td>Anti-Ma2</td>
<td>18 (100%)</td>
<td>Limbic, diencephalic, or brainstem encephalopathy</td>
</tr>
<tr>
<td>Neuronal surface antibodies</td>
<td>20</td>
<td>Ovarian cancer (1.7%)</td>
<td>Anti-NMDAR, GABAAγR and AMPAR</td>
<td>13 (5 of whom with cancer)</td>
<td>Limbic encephalopathy</td>
</tr>
<tr>
<td>Hormonal mechanisms</td>
<td>21</td>
<td>Pancreas (2.4%)</td>
<td>II-6 over-expression, blockage of serotonin receptors</td>
<td>46 (76%)</td>
<td>Depression</td>
</tr>
</tbody>
</table>

SCLC: small cell lung cancer; TGCT: testicular germ cell tumor; * adenocarcinoma, large-cell carcinoma, and pleural metastasis of adenocarcinoma; + breast, parotid gland, ovary, colon, kidney, lymphoma, and retroperitoneal carcinoid; ‡ patients who developed pancreatic cancer following the mental illness designation. Incidence is in accordance with data reported by GLOBOCAN 2012.
loss. Clinically, these syndromes share common psychiatric manifestations, ranging from short-term memory impairment to depression and hallucinations.

From a cognitive and behavioral point of view, the most paradigmatic and well-known condition is anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Anti-NMDAR antibodies were first demonstrated in young women with ovarian cancers (eg, teratoma) but have also been identified in patients of both sexes without neoplastic disorders. Depletion of NMDAR has dramatic effects on dopaminergic and cholinergic systems, thus leading to autonomic instability and on the ponto-medullary respiratory network, ultimately resulting in hypoventilation. More importantly, as a prominent result of the GABAergic dysfunction, patients develop a frontostriatal syndrome with anxiety, mania, paranoia, social withdrawal, and stereotypical behavior (echolalia, echopraxia), in accordance with the so-called "NMDAR theory of schizophrenia".

Hormonal mechanisms might also play an important role in the development of depressive symptoms in cancer patients. For instance, pro-inflammatory cytokines are able to trigger the activation of the HPA axis by increasing the level of CRH and vasopressin and to induce, in periphery, the glucocorticoid receptor resistance and the abolition of the inhibitory effect of glucocorticoids on cytokine production.

Along this view, an intriguing and less known body of research concerns the association between pancreatic cancer and alterations in mood possibly due to multiple mechanisms. Depression, anxiety, and suicidal thoughts often precede or accompany the diagnosis. Moreover, depression often occurs before clinical diagnosis; in addition, in later stages of disease, mood disorders are more pronounced in patients with pancreatic cancer than in those with other abdominal tumors. However, the pathophysiology of this correlation remains largely unknown, possibly comprising tumor-induced changes in the neuroendocrine and acid-base systems. In particular, IL-6 over-expression that is induced by pancreatic cancer is known to down-regulate the synthesis of dopamine and norepinephrine, thus interfering with the HPA axis. In addition, pancreatic cancer cells might secrete antibodies that directly block serotonin receptors or reduce their synaptic availability in the central nervous system (CNS).

Neuroimaging

Morphological magnetic resonance imaging (MRI) is normal in most cases, with the exception of anti-NMDAR encephalitis, for which approximately 50% of patients show T2 or FLAIR signal hyperintensity in the hippocampus, cerebellar or cerebral cortex, frontobasal and insular regions, and, occasionally, the spinal cord. The findings are usually mild or transient and can be accompanied by contrast enhancement in the meninges.

In depressed patients with cancer, brain increased inflammation, as reflected by plasma C-reactive protein and inflammatory cytokine levels, was associated with decreased brain connectivity studied with MRI within reward-related brain regions. Therefore, cancer-induced inflammatory status might induce decreased motivation, anhedonia, and psychomotor slowing, which are common in depressive syndromes. Furthermore, in breast cancer survivors, a resting state connectivity MRI study showed that fatigued patients exhibited greater connectivity between the inferior parietal lobule (IPL) and superior frontal gyrus (SFG), and between the medial prefrontal area and the IPL, and the degree of this increased connectivity was positively correlated with fatigue score, indicating an altered response of the resting state network to internal sensory input in fatigued subjects. In the same patients, functional connectivity in the dorsal attention network decreases at 1 month and recovers 1 year after chemotherapy (CT) treatment in breast cancer survivors (Figure 1).

Using proton magnetic resonance spectroscopy, differences in brain metabolites were shown in the posterior insula between fatigued and non-fatigued breast cancer survivors. In another interesting study, patients affected by lung cancer before treatment demonstrated an alteration of glutamate concentration in the occipital cortex. The relevance of this observation stands in the demonstration of an alteration of brain metabolism in cancer patients even before treatment.

Cognitive Changes

Cancer-related cognitive impairment is observed in severe, subacute clinical conditions (such as immune-mediated encephalitis or vitamin deficiency encephalopathy), or in chronic forms of cognitive decline (see Table 2).
236 lead to excellent clinical improvement.

234 may induce malabsorption through the loss gastrointestinal surgery
231 deficiency for many reasons: thiamine intake could be
229 sible memory deficit with confabulation (Korsakoff
227 confusion, impaired memory, and decreased attention are
225 a triad of signs including eye movement disorders,
222 syndrome). Cancer patients are at risk of vitamin
220 better outcome.46 And, if treated, anti-NMDA encephalitis has generally a
219 antibodies is reversible so that neuronal damage is limited
218 contrary, synaptic interference mediated by cell-surface
217 intracellular antibodies), prognosis is usually poor and
216 depends on the extension of cerebral lesions; on the
215 information due to dysfunction of the mesial temporal lobe
214 mation and necrosis (classic limbic encephalitis with
213 neuropsychological examination Variable
212 seizures are frequent and sometimes progress to status
210 cognition may fluctuate, and the level of consciousness
209 especially during the early stages of disease. Altered
208 symptoms are very common and often predominate,
207 psychosis, aggression, and compulsive behavior); the latter
206 psychiatric symptoms (including depression, agitation and
205 (particularly the hippocampus), behavioral changes, and
204 information due to dysfunction of the mesial temporal lobe
203 predictive changes persist only in a minority (17%
202 relatable short period (1–2 years post treatment); in most
201 Paraneoplastic limbic encephalitis44 is characterized by
200 worse cognitive performance than non-cancer controls.53
200 cognitively impaired than non-cancer controls.50 The risk
200 cognitive impairment is approximately 3.5 times
200 cognitive disorders (observed in up to 75%) appear
200 studies have reported cognitive dysfunction frequencies
200 after therapy (up to 20 years) patients continue to exhibit
200 course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 of cognitive impairment is approximately 3.5 times
200 studies, the effect of cancer therapy was studied for a
200 higher in treated (with chemotherapy) women affected
200 worst cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 patients who suffer cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 patients who suffer cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 after therapy (up to 20 years) patients continue to exhibit
200 course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53
200 studies have reported cognitive dysfunction frequencies
200 than cognitive impairment during the course of the cancer depending on the tissue affected; studies have reported cognitive dysfunction frequencies
200 breast cancer than in untreated patients.51 In most
200 worse cognitive performance than non-cancer controls.53

**Neuropsychological assessment**

Cognitive impairment affects memory and attention. Specifically, patients have difficulties in learning new information and remembering appointments, and exhibit an enhanced forgetfulness that can interfere with daily living activities. An impairment in executive function also occurs, such as difficulties in planning daily programs or implementing strategies that require mental flexibility to cope with future needs and unforeseen events. This type of memory and attention complication is indicative of a frontal-subcortical profile44 and is suggestive of diffuse brain dysfunction.55

Although cognitive impairment in oncological patients has been measured using a variety of tests, the...
affected domains are consistent: processing speed, executive function, and working memory are most strongly affected. An issue that is often discussed in cancer-related cognition assessment is whether cognitive impairments are better measured using self-reporting questionnaires or objective neuropsychological testing. Perceived cognitive impairment (PCI) is one of the most prevalent symptoms, and accurate subjective reports of cognitive impairment might be useful. The International Cognition and Cancer Task Force suggested a core battery test that can identify the domains that are mainly affected: the Hopkins Verbal Learning Test-Revised (HVLT-R) to test learning and memory, the Trail Making Test to test executive function and attention, and the Controlled Oral Word Association of the Multilingual Aphasia Examination to measure the speed of lexical fluency. The authors added that this basic examination could be completed by additional tests of working memory.

Management

Although modafinil and methylphenidate can improve cognition, they have side-effects. Donepezil has been also tested in cancer patients with cognitive impairment. Small improvements were described, but these findings require confirmation using larger and more conclusive trials. Nonpharmacological approaches enhance cognitive performance and perceived cognitive functioning. Rehabilitation programs include direct cognitive rehabilitation or compensatory training that addresses executive functioning and attention, processing speed, working and long-term memory, and visual-spatial skills. Most studies have shown significant improvements in objective and subjective cognitive performance and in quality of life in patients undergoing rehabilitation. Treated patients also showed better improvement in non-trained skills and better managed other psychological symptoms, such as anxiety, depression, and fatigue, and improved sleep quality. Cognitive training appears to be the most effective for groups and individuals. However, coping strategies such as cognitive-behavioral therapy (CBT) or restorative and mindfulness-based stress reduction programs have been proposed to improve cognitive functions, and encouraging results emerged. Some improvements were reported with physical exercise and yoga practice, but these studies involved small sample sizes and different types of exercise programs.

Affective and Behavioral Changes

Patients with cancer are particularly vulnerable to the development of behavioral alterations and psychiatric disorders, which may in turn affect the course and outcome of the primary oncologic disease. Therefore, to implement the appropriate therapeutic intervention, it is important to establish a psychopathological diagnosis by differentiating expected emotional reactions from isolated symptoms (e.g., anger or irritability) and syndromes (e.g., adjustment disorders or major depressive disorder).

Several factors need to be considered regarding the etiology and pathophysiology of the behavioral alterations and psychiatric disorders that occur after cancer diagnosis. For instance, the stress, diagnosis, and treatment of cancer may cause substantial psychiatric morbidity. From a symptomatic perspective, moreover, acute anxiety, depression with despair, agitation, irritability, poor therapeutic adherence, anger, and sleep disturbances may be linked with the emotional and behavioral dimensions of pain. In addition, there are established risk factors for affective disorders and behavioral alterations after cancer diagnosis. These may be related to the cancer (e.g., advanced cancers, certain types of cancer, being physically weakened by cancer) or not (e.g., having a personal history or a positive family history of mental disorders, being unmarried). Finally, family members and caregivers of patients with cancers are also at higher risk for the development of behavioral alterations and mental disorders.

Although the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition acknowledges the possibility of diagnosing several types of mental disorders in patients suffering from cancer, the most frequently reported conditions are depressive, anxiety, trauma-, and stressor-related disorders (see Figure 2 and Table 3). Such conditions can occur at different stages of the illness: when patients receive the diagnosis, when they initiate treatment, and after they achieve remission. Prevalence rates of depression in cancer patients ranging from 8% to 25% have been reported. In a recent meta-analytic investigation, Mitchell et al included 24 studies involving 4007 patients across seven countries in palliative-care settings. The pooled prevalence of depressive disorders, as identified through DSM or ICD criteria, was 16.5% (14.3% major depression and 9.6% minor depression); the prevalence of adjustment disorder was 15.4%, and the prevalence of anxiety disorders was 9.8%. Co-occurring diagnoses were common. All types of depression were found to occur in 20.7%, depression or adjustment disorder in 31.6%, and any mood disorder in 38.2% of the patients. Notably, adjustment disorder with depressed and/or anxious mood was the most common diagnosis (68%).

Another distinct syndrome to take into consideration when assessing depression is demoralization, which has been described as a specific and different condition of...
existential distress in individuals at the end of their life. Patients describe feelings of hopelessness and/or helplessness, which are often related to the experience of a loss of meaning in life. Certain symptoms may overlap with major depression. Demoralization in the medically ill population recently showed prevalence rates ranging from 20.6% to 33.3% of cases. Anxiety disorders have been variably associated with the diagnosis and treatment of cancer, and their prevalence can paradoxically increase after the treatment of cancer is concluded, because patients may feel more vulnerable. The prevalence of posttraumatic stress disorder (PTSD) in cancer patients ranges from 5% to 19%. The lifetime prevalence rates of affective disorders in patients with ovarian and prostate cancers in pre-, during-, and post-treatment settings range from 8% to 27%. Patients with head and neck cancer were found to show the highest rates of major depressive disorder among oncological patients, with an incidence of 15%-50%. Previously, depression has been strongly associated with oropharyngeal (22%-57%), pancreatic (33%-50%), breast (1.5%-46%), and lung (11%-44%) cancer, with lower rates in in patients affected by other forms of cancer, such as colon (13%-25%) and gynecological (12%-23%) cancers and lymphoma (8%-19%).

In terms of prognosis, evidence showing that depression is responsible for significant suffering and distress, reduces participation in medical care, and can prolong the hospital stay needs to be particularly taken into account. The suicide incidence in cancer was found to be approximately double that in the general population. Diagnoses specifically associated with higher suicide rates include prostate, lung, pancreatic, head, and neck cancers, with the first year after diagnosis carrying a higher risk for suicide.

Management

Though the treatment of major depression and other comorbid psychiatric disorders improves the quality of life in patients with cancer, fewer than half of patients receive psychopharmacological treatment. In addition, the treatment of depression has proven to increase patient satisfaction with oncologic treatments and related compliance. Recommendations on the use of psychotropic medications in oncologic patients have been formulated by dedicated task forces and guidelines are available. The efficacy of antidepressants in oncology is well established on the basis of randomized, controlled studies. Thekdi et al reported that selective serotonin reuptake inhibitors (SSRIs) represent the first choice for the treatment of depression and generalized anxiety and the prevention of panic attacks in cancer patients. Benzodiazepines are considered well-tolerated, safe, and effective treatments in the short-term, although their long-term use can induce tolerance and reduced efficacy. Other antidepressants, such as mirtazapine and bupropion, were found to effectively target not only depression and anxiety but also symptoms like sleep alterations, nausea, anorexia, fatigue, reduced concentration, and nicotine dependence, even though their tolerability in patients with anxiety may be problematic. Several drugs are helpful for the adjuvant treatment of cancer-related symptoms, such as, for instance, psychostimulants for fatigue. Benzodiazepines are particularly useful for the treatment of insomnia and, when combined with anti-emetics, were found to relieve chemotherapy-induced nausea and vomiting. Neuropathic pain may benefit from adjuvant treatment with selective serotonin norepinephrine reuptake inhibitors (SNRIs), low-dose tricyclic antidepressants, and SSRIs. An effective psychopharmacological integrated treatment is mandatory in cancer patients given the evidence that untreated psychiatric comorbidity is associated with higher disability, poorer quality of life, and reduced adherence to cancer treatment.

If, on one hand, different psychopharmacological treatments can be effective in ameliorating various cancer-related psychiatric symptoms, on the other hand, some commonly used psychotropics can interfere with the progression of specific forms of cancer and with the action
TABLE 3. Affective and behavioral disorders in patients with cancer

<table>
<thead>
<tr>
<th>References</th>
<th>Design</th>
<th>Cancer type (worldwide incidence as a percentage of all the tumors)</th>
<th>Affective and behavioral disorder</th>
<th>Prevalence</th>
<th>Diagnostic tools</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>71</td>
<td>Research investigation</td>
<td>Various</td>
<td>Adjustment Disorder</td>
<td>68%</td>
<td>DSM III, SCL-90-R, RDS, GAIS, KPS</td>
<td>Unspecified</td>
</tr>
<tr>
<td>66</td>
<td>Meta-analysis</td>
<td>Various</td>
<td>Depression; Adjustment disorder; Anxiety</td>
<td>24%</td>
<td>Standardized criteria and semi-structured interviews</td>
<td>Unspecified</td>
</tr>
<tr>
<td>69</td>
<td>Review</td>
<td>Various</td>
<td>Depression</td>
<td>20–25%</td>
<td>MMPI, DSM-III, HAD, PSE, BDI, BSI, GHQ</td>
<td>Psychological, pharmacological interventions, or a combination of psychological interventions</td>
</tr>
<tr>
<td>77</td>
<td>Review</td>
<td>Head and neck cancer (3%)</td>
<td>Depression</td>
<td>15–50%</td>
<td>Unspecified</td>
<td>Pharmacological, social, and psychological interventions</td>
</tr>
<tr>
<td>70</td>
<td>Meta-analysis</td>
<td>Various</td>
<td>Depression</td>
<td>8–24%</td>
<td>HADS depression subscale, CES-D, BDI</td>
<td>Unspecified</td>
</tr>
<tr>
<td>75</td>
<td>Meta-analysis</td>
<td>Prostate cancer (7.8%)</td>
<td>Depression</td>
<td>17.27%, on-treatment 14.70%, post-treatment 18.44%</td>
<td>HADS, STAI, CES-D, SCL, BDI, SRAS, SRDS, BSI, CIDI</td>
<td>Unspecified</td>
</tr>
<tr>
<td>76</td>
<td>Meta-analysis</td>
<td>Ovarian cancer (1.7%)</td>
<td>Depression</td>
<td>17.27%, on-treatment 14.70%, post-treatment 18.44%</td>
<td>Anxiety Scale for Prostate Cancer and the Effects of Prostate Cancer on Lifestyle Questionnaire.</td>
<td>Unspecified</td>
</tr>
<tr>
<td>78</td>
<td>Review</td>
<td>Various</td>
<td>Depression</td>
<td>0–38%</td>
<td>HADS, BDI, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, and DSM criteria</td>
<td>Antidepressants</td>
</tr>
<tr>
<td>72</td>
<td>Review</td>
<td>Various</td>
<td>Demoralization syndrome</td>
<td>13–18%</td>
<td>DS, DCPR</td>
<td>Antidepressants and psychotherapy (depression comorbidity)</td>
</tr>
<tr>
<td>74</td>
<td>Review</td>
<td>Various</td>
<td>Posttraumatic stress disorder</td>
<td>5–19%</td>
<td>PCL-C and semi-structured interviews</td>
<td>Psychological, pharmacological interventions or a combination</td>
</tr>
</tbody>
</table>

BDI: Beck Depression Inventory; BSI: Brief Symptom Inventory; CES-D: Center for Epidemiologic Studies-Depression Scale; CIDI: Composite International Diagnostic Interview; DCPR: Diagnostic Criteria for Psychosomatic Research; DS: Demoralization Scale; DSM-III, Diagnostic and Statistical Manual for Disorders, version 3 (Interview assessment); GAIS: General Adjustment to Illness Scale; GHQ: General Health Questionnaire; HAD: Hospital Anxiety and Depression Scale; HADS: Hospital Anxiety and Depression Scale-depression subscale; KPS: Karnofsky performance scale; MMPI: Minnesota Multiphasic Personality Inventory; PCL-C: PTSD (Posttraumatic Stress Disorder) Checklist Civilian Version; PSE: Present State Examination; RDS: Raskin Depression screen; SCID: Structured Clinical Interview for DSM; SCL: Symptom Checklist; SRAS: Self-Rating Anxiety Scale; SRDS: Self-Rating Depression Scale; STAI: State-Trait Anxiety Scale. Incidence is in accordance with data reported by GLOBOCAN 2012.22
of certain antineoplastic drugs. Among the former, for instance, several antipsychotics were shown to increase serum prolactin, and hyperprolactinemia has been linked, in turn, to the development of mammary gland tumors in animal studies. If, in these cases, second generation antipsychotics should be preferred to neuroleptics, nonetheless, more studies and updated recommendations from treatment guidelines are needed to assess pros and cons of undertreatment of serious psychiatric disorders in patients with cancer, based on unproven contraindications to psychiatric medications.

Another noteworthy issue is represented by the interaction that some antineoplastic drugs may have with psychotropic drugs that interfere with cytochrome P450 (CYP). One of the most studied cases in the field is represented by tamoxifen, an adjuvant hormonal therapy that is widely used for estrogen receptor positive metastatic breast cancer. Given that tamoxifen is metabolized to its more active form (endoxifen) by CYP2D6, decreases in CYP2D6 activity due to interactions with psychotropic drugs that inhibit it (eg, paroxetine and fluoxetine) may reduce the activity of tamoxifen and confer an increased risk of recurrence. If, in such contexts, psychotropic drugs that do not interfere with the activity of CYP2D6 should be preferred, recent data in the field have assessed the available evidence in a more balanced way, recommending caution and considering clinical aspects that vary from case to case.

Over the last several years, novel approaches for the management of behavioral alterations in patients with cancer have been proposed and examined. Among these, ketamine—a dissociative anesthetic psychotropic compound—has been tested in oncologic patients with treatment-resistant depression and suicidal ideation with encouraging results. As for non-oncologic psychiatric patients, however, it remains to be further clarified whether the role of ketamine is maintained beyond the short-term. Other authors have hypothesized that brain stimulation techniques, particularly non-invasive interventions like repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), might be helpful for patients with cancer and psychiatric symptoms in light of their selective action, lack of systemic effects, and no interaction with concomitant antineoplastic drugs. However, no controlled investigation is currently available to endorse an approach of this kind.

Chemotherapy- and Radiotherapy-Induced Disturbances

Several studies have shown chemotherapy-related cognitive dysfunction (see Table 4). The design of these studies was mainly cross sectional: the cognitive function of treated patients was compared with matched controls, and the identification of significant cognitive impairments in the chemotherapy groups addressed the pathogenetic role of cytotoxic agents. Although such studies were fundamental to validating the cognitive complaints of cancer patients, they did not control for confounding factors. Yet, cancer patients may complain of cognitive symptoms before any treatment. Consequently, more recently the study design changed; dismissing a cross-sectional experimental design, prospective studies were conducted. Regardless of the study design used, breast cancer patients who were treated

### TABLE 4. Chemo- and radiotherapy-associated cognitive impairment

<table>
<thead>
<tr>
<th>Therapy</th>
<th>References</th>
<th>Primary disease</th>
<th>Symptoms and clinical syndromes</th>
<th>Dose of radiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy (CT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAC</td>
<td>50, 104, 117</td>
<td>Breast</td>
<td>Attention, processing speed, learning, memory, executive and visuospatial function, motor skills</td>
<td></td>
</tr>
<tr>
<td>FEC or CTC</td>
<td>118</td>
<td>Breast</td>
<td>Attention, working, visual and verbal memory, executive and visuospatial function, motor skills</td>
<td></td>
</tr>
<tr>
<td>FEC, DCP or DC</td>
<td>119</td>
<td>Breast</td>
<td>Attention, working, visual, and verbal memory</td>
<td></td>
</tr>
<tr>
<td>AAT</td>
<td>37, 113-115</td>
<td>Prostate</td>
<td>Visual and visuospatial memory and processing, reaction time, working memory</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy (RT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>Neck</td>
<td>Mild cognitive impairment (only in 20%)</td>
<td>4,140-6,500 cGy at tumor site, 3,000 cGy for the whole brain</td>
<td></td>
</tr>
<tr>
<td>121</td>
<td>rhabdomyosarcoma</td>
<td>Attention, complex cognition</td>
<td>Not reported</td>
<td></td>
</tr>
<tr>
<td>122</td>
<td>Breast</td>
<td>Executive functions, processing speed</td>
<td>Mean dose ≈ 5900-6000 (±600) cGy</td>
<td></td>
</tr>
<tr>
<td>123</td>
<td>Breast§</td>
<td>Verbal memory</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FAC: 5-fluorouracil, doxorubicin, and cyclophosphamide; FEC: 5-fluorouracil, epirubicin, and cyclophosphamide; CTC: cyclophosphamide, thiopeta, and carboplatin; DCP: doxorubicin, cyclophosphamide, and paclitaxel; AAT: androgen ablation therapy. § RT in combination with CT.
with cytotoxic agents showed a cognitive decline relative to their pre-treatment cognitive status and to breast cancer patients without chemotherapy and non-cancer controls over the same period. Specific drugs may have different effects. Fluorouracil can induce hyperammonemia, thus causing hyperammonemic encephalopathy, whose clinical manifestations range from psychomotor slowing and flapping tremor to severe consciousness disturbances. Also, luteinizing hormone-releasing hormone (LHRH) agonists are associated with non-norsteroidal antiandrogens to obtain a combined androgen blockage, and this treatment can cause neurological disturbances such as visuomotor slowing, slowed reaction times, and impaired working memory.

Several trials found a correlation between cognitive dysfunction and chemotherapy in women with non-metastatic breast tumors. This association is termed "chemobrain." In women receiving a regimen of 5-fluorouracil, doxorubicin, and cyclophosphamide, Wefel et al showed that approximately 60% of patients experienced a cognitive decline with decreased attention, learning, and processing speed, thus suggesting a disruption in frontal network systems. Interestingly, many patients improved 1 year after completing 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) therapy, especially when work-related abilities were tested. In this context, it is worth noting that before the initiation of systemic adjuvant therapy, women with breast cancer exhibited declines in a wide range of cognitive functions, involving verbal learning, nonverbal memory, confrontational naming, complex visuoconstruction, and fine motor dexterity. Women treated with tamoxifen for breast cancer have lower brain concentrations of myo-inositol. Tamoxifen induces areas of hypometabolism in the inferior and dorsal lateral frontal lobes and decreases right hippocampal volumes.

The irradiation of head and neck tumors (in particular cancer of the nasopharynx and paranasal sinuses) might cause radiation-induced vascular damage in the medial temporal lobe, thus affecting memory. Irradiation triggers an inflammatory response with endothelial injury. Paulino et al reported intellectual and academic delays in 3 out of 30 children who had received megavoltage radiotherapy for head and neck rhabdomyosarcoma. A moderate general developmental delay including pronounced motor deficits that were associated with various levels of perceptual and cognitive problems was observed in all children treated with total brain irradiation prior to bone marrow transplantation. Cognitive impairment accompanying radiotherapy has also been reported after the irradiation of body regions that are distant from the brain, in particular for non-metastatic breast cancer treatment, possibly by increasing levels of IL-6. Radiation dose, site of primary tumor, and the timing of association with chemotherapy (CT) are variable (Table 4), and further studies are needed to assess possible cognitive and behavioral effects induced by tissues irradiation. Overall, while CT has a specific negative effect on verbal fluency, breast cancer treatment in general negatively affects verbal memory. However, cognitive impairment induced by either CT or radiation therapy is probably mild, and difficult to disentangle from that due to primary disease.

Relevance of Neuropsychopathological Abnormalities for the Clinical Outcome

Depressive symptoms and psychosocial stressors can be considered risk factors for cancer incidence and mortality by affecting several neuroimmunological and neuroendocrinological biochemical pathways. When a potentially risky event is perceived by the subject as overwhelming the available resources (such as coping strategies and social support), the nervous system activates pathways that release catecholamines, corticosteroids, and opioids. Because the receptors for these chemical signals (neurotransmitters, neuropeptides, neurohormones, and adrenal hormones) are also located on lymphocytes and macrophages, the release of these cerebral messengers can influence immune and endocrine functionality (see Figure 3) in vivo and in vitro.

Through these mechanisms the brain exerts an immunoregulatory role in oncologic diseases. For example, the plasma concentration of epinephrine, which is associated with intense emotions, especially fear, is inversely related to specific immune functions in lymphocytes and monocytes. The experience of stressful events is concomitant with the release of high concentrations of corticosteroids that have important immunosuppressive effects on the functions of lymphocytes and macrophages and might affect their circulation patterns.

In this context, psychological interventions during oncologic treatments are important resources that aim to improve psychological conditions and therefore revert...
dysfunctional immunological and endocrinal mechanisms with consequent positive effects on the disease. Studies have reported the improvement of immunological parameters (eg, lymphocyte proliferation and their related physiologic values (eg, cortisol levels) in patients who attended psychological support sessions. Andersen et al examined the influences of a psychosocial treatment on survival and recurrence (227 women with non-metastatic breast cancer) immediately after surgery. Psychological intervention included training for relaxation and stress reduction, coping skills implementation, and strategies to change health behavior related to nutrition and physical activity. The treatment group showed a significant decrease in overall and breast cancer–specific mortality rates, and the risk of cancer recurrence was reduced by 45% at a median of 11 years follow-up.

Studies on cancer survivors have emphasized the role of positive emotions, resilience, and optimism in contributing to better adjustment and quality of life. Empirical evidence has shown that these protective psychological factors predict better coping among cancer patients. Because stress impacts on neuroendocrine and neuro-immunological mechanisms influencing tumor onset, progression, and recurrence (eg, ovarian cancer), psychosocial and psychoeducational interventions must be considered an integral part of cancer treatment.

The integrity of cognitive aspects (such as attention, perception, and thought) may indirectly influence cancer incidence and progression from pre-clinical conditions. For example, conditions of depression and distress may impact on perceptions of risk and on decision-making strategies leading to the adoption of risky behaviors (such as smoking, alcohol and drug consumption), which in turn could cause immunological and endocrinal changes. Moreover, a condition of distress and a bad patient–physician relationship has been shown to influence adherence to medical prescription and to interfere with attendance at screening procedures (such as mammography) and with active surveillance of tumors with low metastatic potential. In conclusion, making decisions, especially about healthcare, is not a linear process; patients’ viewpoints are influenced by cognitive (eg, biases and heuristics) and emotional factors (eg, intense emotional expressions), which modulate the presentation and interpretation of medical information. It is extremely important that patients are supported in order to not succumb to cognitive biases and to allocate attention efficiently to improve comprehension and make optimal decisions.

**Clinical Implications**

Cancer can induce neuropsychological and behavioral abnormalities through different mechanisms, with several practical implications. First, every patient reporting an abrupt onset of mood or cognitive dysfunction without a clear hereditary predisposition or other immediately evident environmental or medical cause should be screened also for the possible presence of cancer. Similarly, patients affected by a chronic psychiatric disorder exhibiting a sudden change of their psychopathological or cognitive picture should be screened for cancer also. Yet, as discussed above, several tumors may appear as mild cognitive or psychiatric disturbances months before they become manifest. Second, clinicians should bear in mind that the decision-making capacity in patients with cancer can be impaired, yielding forensic implications. Finally, but perhaps most importantly, the data reviewed above indicated the importance of interventions that aim to restore normal cognitive and behavioral conditions. Because psychological and cognitive wellness importantly contribute to the quality of life in patients with cancer, clinicians, in addition to treating the primary manifestation of cancer, should always carefully search for and treat cognitive and mood abnormalities.

Although there are no systematic data, our experience is that patients undergoing chemotherapy should be carefully evaluated for their driving ability.

We therefore propose that every patient accessing a cancer hospital should be formally screened for cognitive, psychiatric, or psychological abnormalities that, if present, should be immediately treated. To ensure this, a multidisciplinary team comprising neurologists, psychiatrists, neuropsychologists, and psychologists is recommended in all cancer centers.

**Future Directions**

It is fundamental to expand our frame of reference to explore the neurobiological activities that have been related to stress factors and other psycho-social phenomena which may operate in concert with stress-related immunologic and neuroendocriologic changes in influencing disease outcomes. Future challenges consist in demonstrating how psychological processes and interventions influence tumor environmental complexity through underlying mechanisms mediated by stress and negative emotionality and related to the clinical course of disease. To understand these phenomena in depth, new study designs and consequent paradigms of cure should be tested.

First, it could be useful to develop a translational human-animal design to investigate specific targets of tumorigenic activity determined by stress using a murine model. Moreover, in everyday clinical practice a new therapeutic approach, which encompasses a stronger neuro-psycho-oncological intervention, should be adopted. As already demonstrated by previous research,
stress management interventions for cancer patients 
have promising effects on psychological aspects, tumor-
related factors, and prognosis and should be included 
on oncologic routine care. Future study designs should
focus on ameliorating psychological treatment and 
support during the management of the oncologic 
disease. This endpoint could be achieved through the 
personalization of interventions, which, according to the 
patients’ needs, could include sessions that enhance 
decision-making strategies and/or coping skills. In this 
framework, the assessment of patients’ cognitive and 
psycho-emotional factors would be important in order 
to draw individual profiles and customize treatment.

Simple interactive tools (ie, an “app” for cell phones and 
tables) to explore patients’ preferences giving immedi-
ate feedback (for example about drugs characteristics or 
side effects) to physicians, and to help patients in every 
day choices regarding the disease, may constitute a useful 
and innovative way to face the pathology.

Disclosures

Bernardo Dell’Osso, Gabriella Pravettoni, Tommaso 
Bocci, Francesca Cortese, Alberto Priori, Chiara Rosci, 
Roberta Ferrucci, and Valentina Lampis have nothing 
to disclose.

REFERENCES:

1. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. 
From inflammation to sickness and depression: when the immune 
neuroimmunologic mechanism of cancer-related symptoms. 
Neuroendocrine-immune mechanisms of behavioral comorbidities 
4. Dantzer R. Cytokine-induced sickness behavior: where do 
depressive symptoms and proinflammatory cytokine elevations 
in women undergoing primary treatment for breast cancer. 
siCAM-1 and depressive symptoms during adjuvant treatment 
7. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. 
Association between decreased serum cytokine concentrations 
and depressive symptoms in cancer patients undergoing cytokine 
8. Wirleitner B, Neurauter G, Schroecksnadel K, Frick B, Fuchs D. 
Interferon-gamma-induced conversion of tryptophan: 
1581–1591.
hematological neoplasias is associated with immune system 
10. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, 
Allen-Mersh TG. Trypophan and quality of life in 
tryptophan in patients with cancer cachexia correlates with 
increased serum neopterin. Immunol Invest. 1995; 24(3): 
467–476.
nervous system neuronal surface antibody associated syndromes: 
review and guidelines for recognition. J Neurol Neurosurg 
and Salivary cortisol as new biomarkers of depression in lung 
cancer patients. Prog Neuropsychopharmacol Biol Psychiatry. 
15. Hufner K., et al. Levels in neurotransmitter precursor amino acids 
related with mental health in patients with breast cancer. 
16. Fukami Y., et al. [Following sensory neuropathy, anti-Hu antibody-
positive paraneoplastic neurological syndrome presenting with 
limbic encephalitis occurs after complete remission]. Rinsho 
17. Funagachi N., et al. [Paraneoplastic neurological syndrome 
accompanied by severe central hyperventilation and expression of 
anti-Hu antibody in a patient with small cell lung cancer]. Nihon 
18. Gultekin S.H., et al. Paraneoplastic limbic encephalitis: 
nervous system, immunological findings and tumour 
20. Dogan Onugoren M., et al. Limbic encephalitis due to GABAB and 
AMPA receptor antibodies: a case series. J Neurol Neurosurg 
symptoms in carcinoma of the pancreas with those in some other 
1553–1562.
Immunochemical analysis of anti-Hu-associated 
103(5): 509–515.
analysis in anti-Hu associated paraneoplastic encephalomyelitis. 
25. Kayser MS, Kohler G, Dalman J. Psychiatric manifestations of 
1039–1050.
encephalitis: temporal progression of clinical and paraclinical 
observations in a predominantly non-paraneoplastic disorder of 
encephalitis: case series and analysis of the effects of antibiotics. 
28. Dalman J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, 
Balice-Gordon B. Clinical experience and laboratory 
investigations in patients with anti-NMDAR encephalitis. Lancet 
29. Olney JW, Farber NB. Glutamate receptor dysfunction and 
1026 the Hoosier Oncology Group.

1025 placebo in advanced cancer outpatients: a double-blinded trial of


1036 86. Rayner L, Price A, Hotopf M, Higginson IJ. The development of disorders and select comorbid medical conditions.


